Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand  by Miura, Yuji et al.
C
i
R
I
(
t
f
p
d
f
t
g
Biology of Blood and Marrow Transplantation 10:156-170 (2004)
 2004 American Society for Blood and Marrow Transplantation
1083-8791/04/1003-0002$30.00/0
doi:10.1016/j.bbmt.2003.10.005
1ytolytic Effector Mechanisms and Gene Expression
n Autologous Graft-versus-Host Disease: Distinct
oles of Perforin and Fas Ligand
Yuji Miura, Christopher J. Thoburn, Emilie C. Bright, Allan D. Hess
The Sidney Kimmel Comprehensive Cancer Research Center at Johns Hopkins University, Baltimore, Maryland
Correspondence and reprint requests: Allan D. Hess, PhD, The Sidney Kimmel Comprehensive Cancer Research
Center at Johns Hopkins University, 1650 Orleans St., Room 484, Baltimore, MD 21231 (e-mail: adhess@jhmi.edu).
Received September 15, 2003; accepted October 21, 2003
ABSTRACT
The administration of cyclosporin A (CsA) after autologous stem cell transplantation (SCT) paradoxically
elicits a systemic autoimmune syndrome that resembles graft-versus-host disease (GVHD); this is termed
autologous GVHD (autoGVHD). Although dominated by activated CD8 cytotoxic T lymphocytes, the
complex cellular reaction also includes CD4 T cells and involves multiple effector mechanisms. To determine
the temporal development and relative importance of these mechanisms in autoGVHD, perforin/granzyme,
Fas ligand (FasL), interferon- (IFN-), tumor necrosis factor (TNF)-, and interleukin-18 gene expression in
peripheral blood mononuclear cells was examined in 36 patients treated with CsA after SCT. Quantitative
real-time polymerase chain reaction analysis revealed that perforin/granzyme B, TNF-, and interleukin-18
messenger RNA (mRNA) levels in peripheral blood mononuclear cells from patients in whom autoGVHD
developed were markedly higher (and temporally associated with the onset of autoaggression) compared with
the levels detected in healthy individuals and in control, non–CsA-treated SCT patients. It is interesting to
note that patients in whom autoGVHD did not develop also demonstrated increased mRNA levels for these
cytokines: however, expression was substantially lower compared with that in patients with autoGVHD. It is
important to note that IFN- mRNA levels were selectively increased in CD8 cells only from patients in
whom autoGVHD developed. The development of autocytolytic T cells in autoGVHD correlated with
increased expression of perforin, IFN-, and TNF- mRNA. Furthermore, enhanced autoreactive T-cell
activity and the induction of autoGVHD was also concordant with perforin and TNF- mRNA upregulation
in CD4 cells. Surprisingly, FasL mRNA levels were significantly decreased, with a progressive loss of FasL
mRNA expression as autocytolytic activity increased. These findings suggest that IFN-/perforin–based CD8
cytotoxic T lymphocytes seem to play a dominant role in autoGVHD and that TNF-/perforin–based CD4
cells may amplify this autoaggressive syndrome. The FasL pathway may play an important role in the regulation
of this immune syndrome.
© 2004 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Induction of autologous graft-versus-host disease
autoGVHD) after autologous stem cell transplanta-
ion (SCT) has been a potential therapeutic modality
or patients with hematologic malignancies and for
atients with breast cancer. AutoGVHD can be in-
uced by the administration of cyclosporin A (CsA)
or a limited period after SCT [1-7]. Initial clinical
rials in patients with hematologic malignancies sug-
est that the induction of autoGVHD can reduce the t
56ate of relapse [8-11]. The therapeutic beneﬁts are
erived not only from the high doses of chemotherapy
r irradiation used in the preparative regimen, but also
rom the eradication of residual tumor cells by auto-
eactive T lymphocytes.
The induction of autoGVHD is a 2-tiered process
hat requires both the active inhibition of the thymic-
ependent clonal deletion of autoreactive T cells and
he elimination of a peripheral immunoregulatory sys-
em by the preparative regimen; this provides a per-
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Effector Mechanisms in Autologous GVHD
Bissive environment for the autoreactive T cells to
anifest autoaggression [2,3]. Reconstitution of the
mmunoregulatory system alters the course of autoag-
ressive disease. The onset of autoGVHD is charac-
erized by a vigorous cell-mediated immune response
ith the proliferation of autoreactive CD8 cytotoxic
lymphocytes (CTLs) that promiscuously recognize
ajor histocompatibility complex (MHC) class II de-
erminants, a process that is dependent on presenta-
ion and recognition of the MHC class II invariant
hain peptide [12-14]. The activity of the effector
D8 T cells is potentiated by an autoreactive CD4
-cell subset [3,4]. Natural killer (NK) cells also seem
o contribute signiﬁcantly to the development of au-
oGVHD [15,16]. These autoreactive lymphocytes
an lyse a variety of tumor cell lines derived from
atients with myeloma, lymphoma, and breast cancer
12,13]. Together, these effector mechanisms primar-
ly mediate dermal pathology with the epithelial cell
estruction that is characteristic of GVHD after allo-
eneic SCT.
Immune-mediated cell killing can occur by several
istinct mechanisms, including cytokine induction of
ell death, cell-mediated lysis through the perforin/
ranzyme system, or Fas/Fas ligand (FasL) interac-
ions [17,18]. CTLs, including CD4 T cells, CD8
cells, and NK cells, can kill a variety of target cells
ie, virally infected cells and tumor cells) by using 1 or
ore of these pathways. Cytotoxic lymphocytes can
ecrete cytotoxic cytokines such as interferon (IFN)-
nd tumor necrosis factor (TNF)- with a direct local
ffect on the target cells [19]. Alternatively, CTLs can
ake direct contact with target cells by using their
lonotypic T-cell receptor for antigen. Contact-de-
endent cytotoxic lymphocyte–induced death can oc-
ur by either the secretion of cytotoxic granules onto
he surface of the target cells (perforin/granzyme
athway) or by the interaction of FasL on the CTLs
nd the Fas receptor on the target cells (Fas/FasL
athway), leading to apoptotic cell death [20]. Al-
hough several recent studies have demonstrated that
oth perforin and Fas/FasL pathways are important
or the development of allogeneic GVHD (al-
oGVHD) [21-27], the molecular effector mecha-
isms used by the autoreactive T cells in the novel
utoaggression syndrome, autoGVHD, remain un-
lear.
To evaluate the mechanisms involved in au-
oGVHD, gene expression for cytotoxic molecules
perforin, FasL, and granzyme A or B) and cytotoxic-
ty-associated cytokines (IFN-, TNF-, interleukin
IL]-12, and IL-18) was examined temporally in pe-
ipheral blood mononuclear cells (PBMCs) from 36
atients undergoing autologous SCT with au-
oGVHD induction. Quantitative real-time polymer-
se chain reaction (PCR) analysis reveals that IFN-/
erforin–based CD8 CTLs seem to play a dominant t
B&MTole in autoGVHD and that TNF-/perforin–based
D4 cells may amplify this autoaggressive syn-
rome. However, FasL messenger RNA (mRNA) lev-
ls are decreased during autoGVHD and exhibit an
nverse temporal relationship with autocytolytic T-
ell activity and maintenance of NK function. These
esults suggest that the Fas/FasL pathway may play an
mportant role in the regulation of this syndrome. The
ytotoxic pathway in autoGVHD is complex and in-
olves synergistic interactions between cellular and
ytokine pathways and distinct subsets of effector
ells. Understanding these pathways may not only
romote more effective immunotherapeutic strategies
o enhance the antitumor efﬁcacy of autoGVHD, but
lso provide insight into the reconstitution of self
olerance after SCT.
ATERIALS AND METHODS
atients
Women from 18 to 60 years of age with metastatic
reast cancer and a complete or partial response to
hemotherapy were included in this study, which was
pproved by the Joint Committee on Clinical Inves-
igation of the Johns Hopkins Hospital, as previously
escribed [13,28]. All patients provided informed
ritten consent. Normal renal, cardiac, pulmonary,
nd hematopoietic reserves, in addition to an Eastern
ooperative Oncology Group performance status of 0
o 1, were required for all patients.
reparative Regimens and Induction of
utoGVHD
The patients were prepared for autologous bone
arrow transplantation by treatment with cyclophos-
hamide (1.5 g/m2) and thiotepa (200 mg/m2; 4 times
aily) before autologous bone marrow rescue [13,28].
utoGVHD was induced by the intravenous admin-
stration of CsA (2.5 mg/kg/d for 28 days; Novartis,
anover, NJ) beginning on the day of transplantation.
ecombinant IFN- (0.025 mg/m2; National Cancer
nstitute, Bethesda, MD) was administered subcutane-
usly every other day from days 7 through 28 [29,30].
ne group of control patients (n  6) underwent
utologous SCT with the same preparative regimens
ut without the administration of CsA and IFN-.
he control patients elected not to receive the au-
oGVHD induction treatment. Four patients who un-
erwent allogeneic SCT and experienced the devel-
pment of grade III to IV acute GVHD were also
ompared with those patients in whom autoGVHD
eveloped. Patients were evaluated daily for evidence
f autoGVHD (erythematous rash). Each biopsy spec-
men was examined by one of the investigators in a
linded fashion. The histologic diagnosis of acute cu-
aneous GVHD was established when at least grade II
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1hanges were present, including basal vacuolar degen-
ration, spongiosis, dyskeratosis, and an inﬁltration of
ymphocytes in the upper dermis and lower epidermis.
ssays were conducted within 24 to 72 hours from the
nset of the rash [13,28].
ell-Mediated Lympholysis Assay
Cytotoxic activity was assessed sequentially after
utologous SCT by using PBMCs isolated by Ficoll-
ypaque density centrifugation. Target cells used in
hese studies included autologous phytohemaggluti-
in-stimulated lymphoblasts (PHA-blasts) cryopre-
erved before transplantation, the breast cancer cell
ine T47D [31,32], and the NK target cell line K562.
he pretransplant lymphocytes were thawed and
timulated with PHA for 72 hours (RPMI 1640; 20%
ormal human serum) before use as targets. The K562
ell line was grown in suspension culture in RPMI
640 tissue culture medium supplemented with 10%
etal calf serum. T47D is an adherent breast cancer
ine grown in Dulbecco modiﬁed Eagle tissue culture
edium supplemented with 5% fetal calf serum, glu-
amine, and sodium pyruvate [31,32]. Before assay, the
ells were mildly trypsinized and grown in Nalgene
eﬂon ﬂasks (Thomas Scientiﬁc, Swedesboro, NJ) for
4 hours to allow for the recovery of cell-surface
ntigens. The target cells were labeled with 250 Ci
f chromium 51 (51Cr) for 1 hour at 37°C and washed
times before the assay. The effector lymphocytes
ere cocultured with 2.5  103 labeled target cells in
riplicate in round-bottomed microtiter wells. After 4
ours of incubation, 51Cr release was assessed, and the
ercentage of speciﬁc lysis was determined from trip-
icate cultures as previously described [13,28].
NA Extraction
Heparinized peripheral blood was collected from
he patients after informed consent was obtained, and
BMCs were separated by using density-gradient cen-
rifugation. Monocytes were isolated by plastic adher-
nce and harvested by gentle scraping (85% CD14
y ﬂow cytometry). Lymphocytes were separated into
istinct T-cell subsets by immunomagnetic bead sep-
ration chromatography by using monoclonal anti-
odies to the CD4 and CD8 cell-surface determi-
ants (Dynal Biotech, Oslo, Norway), as previously
escribed [4,13]. The purity of the isolated CD4 and
D8 cells was typically 97%, as determined ﬂow
ytometrically. Skin biopsy samples (4-mm punch bi-
psies) were obtained, with informed patient consent,
efore transplantation and on the initial development
f erythematous rash. The tissue was frozen in liquid
itrogen and pulverized with a mortar and pestle
33,34]. Total RNA was puriﬁed by dissolving the
owder in Trizol reagent (Life Technologies, Gaith-
rsburg, MD) with adequate mixing. Cell lysate was s
58repared from 5  106 PBMCs by adding 1 mL of
rizol reagent with adequate mixing. After 200 L of
hloroform was added, the solution was well mixed
nd centrifuged. The supernatant was collected and
xtracted once with chloroform. RNA was precipi-
ated with 2-propanol and rinsed with 70% ethanol.
uriﬁed RNA was dissolved in 30 L of diethyl-
yrocarbonate–treated distilled water.
uantification of Cytotoxic Molecule and
ytokine MRNA Levels by Real-Time PCR
Reverse transcription was conducted as follows: 32
L of water containing 1 g of total RNA was added
o 0.4 g of random primers (Life Technologies) and
ncubated at 65°C for 10 minutes. Samples were
hilled on ice, and complementary DNA was prepared
ith Ready-To-Go You-Prime First-Strand kit (Am-
rsham Pharmacia Biotech, Piscataway, NJ), accord-
ng to the manufacturer’s protocol. Real-time PCR
eactions were performed by using the TaqMan assay
Applied Biosystems of PerkinElmer [ABI-PE], Foster
ity, CA), and PCR ampliﬁcations were performed in
he ABI-PE Prism 7700 sequence detection system
35,36]. Brieﬂy, a solution of TaqMan Universal PCR
aster Mix (25 L; ABI-PE) containing sense and
ntisense primers (300 nmol/L each) and dual-labeled
uorogenic probes (100 nmol/L) was prepared and
liquoted into individual MicroAmp Optical Plates
ABI-PE), and 5 L of complementary DNA was
dded to give a ﬁnal volume of 50 L. Conditions for
CR reactions included 50°C for 2 minutes, 95°C for
0 minutes, and 40 cycles of 95°C for 15 seconds
denaturation) and 60°C for 1 minute (annealing/ex-
ension). Data were analyzed with Sequencer Detector
ersion 1.6 software. The threshold cycle (CT) during
he exponential phase of ampliﬁcation was determined
y real-time monitoring of ﬂuorescent emissions after
leavage of sequence-speciﬁc probes by the nuclease
ctivity of Taq polymerase. Glyceraldehyde-3-phos-
hate dehydrogenase (GAPDH) was used as an inter-
al control gene. Primers and ﬂuorogenic probes for
APDH, IFN-, TNF-, FasL, IL-12, and IL-18
ere from TaqMan kits (ABI-PE). The perforin and
ranzyme A and B reagents were generated by using
he speciﬁc primer sequences (Integrated DNA Tech-
ologies, Coralville, IA) shown in Table 1. Messenger
NA levels were expressed as the absolute number of
opies normalized against GAPDH mRNA. The dif-
erence in ampliﬁcation was determined as follows:
/(CTtarget  CTGAPDH)
2. Although levels of the cy-
okine proteins were not determined in this study,
ecent studies in our laboratory have demonstrated
hat the level of cytokine mRNA quantiﬁed by real-
ime PCR directly correlates with cytokine production
y PBMCs from patients with autoGVHD, as mea-
ured by enzyme-linked immunosorbent assays [16].
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Effector Mechanisms in Autologous GVHD
Btatistical Analysis
Data were analyzed by the Fisher exact test or
earson correlation (r) by using StatView software
SAS Institute, Cary, NC), with P values 	.05 consid-
red statistically signiﬁcant.
ESULTS
ytotoxic Activities and AutoGVHD
Cytotoxic molecule/cytokine gene expression and
ytotoxic activity were evaluated in PBMCs from 36
atients treated with CsA after SCT. Clinical GVHD
eveloped in 15 (41.6%) of 36 patients. Table 2 sum-
arizes the data from patients with biopsy-conﬁrmed
utoGVHD, patients without clinical manifestations
f autoGVHD, and control autologous SCT (non–
sA-treated) patients, evaluating maximal cytotoxic
ctivity during the course of treatment or at the onset
f autoGVHD (day 12 through 33). Extensive analy-
es of lytic activity in patients with autoGVHD were
reviously published and are succinctly summarized
elow [13,28]. Cytotoxicity mediated by posttrans-
lantation PBMCs against autologous PHA-blasts
able 1. Target mRNA Primers and Probes
arget mRNA Forward Primer Sequence (5-3) Rev
Perforin CTCACAGGCAGCCAACTTTG GGCA
Granzyme A AAGAAAGAGTTTCCCTATCCATGCTA TTTGC
Granzyme B TGGCGGCATCCTAGTGAGA CCCC
AM indicates 6-carboxyﬂuorescein; TAMRA, 6-carboxytetraethyl
able 2. Lymphocytotoxicity Analysis
Target
Cells
Patients
at Onset
of GVHD
(n  15
patients;
17 time
points)
Patients
without
GVHD
(n  21
patients;
42 time
points)
Control SCT
(Non–CsA-Treated)
Patients
(n  6)
HA-blasts 12.9  4.7* 4.3  0.9 1.5  0.8
47D 24.0  5.0* 12.6  1.7 4.8  1.2
562 53.0  4.4† 42.4  2.4 50.1  6.7
aximum autocytolytic, anti-T47D, and NK cell activity observed
from day 12 through 33 for patients who developed autoGVHD
conﬁrmed by skin biopsy. Data for the onset of GVHD repre-
sent the lytic activity when the patients developed clinical evi-
dence of autoGVHD. The results from patients without clinical
manifestations of autoGVHD or 6 control autologous SCT
(non–CsA-treated) patients are presented for comparison.
Please note that identical results (maximal or minimal levels) on
2 successive determinations for any given patient were included
in the analysis. Lysis of the target cells was measured with a
standard 51Cr release assay at a 100:1 effector target ratio. Data
are expressed as mean SE. PHA-blasts indicates phytohemag-
glutinin-stimulated lymphoblasts.
P 	 .01, †P 	 .05 for patients at the onset of GVHD vs. patients
twithout GVHD.
B&MTdata are presented for autocytolytic activity at the
nset of autoGVHD) was signiﬁcantly (P 	 .01;
ange, 0.8%-25.2% lysis) higher in the patients in
hom autoGVHD developed compared with the con-
rol patients and with patients who did not develop
utoGVHD. Similarly, cytotoxicity against the T47D
ell line mediated by the posttransplantation lympho-
ytes of patients with conﬁrmed autoGVHD was also
igniﬁcantly (P  .04; range, 7.4%-53.7% lysis) en-
anced when compared with that of patients without
utoGVHD and with that of the control group of
on–CsA-treated SCT patients. NK activity of pa-
ients with autoGVHD was not signiﬁcantly different
ompared with the control group but was signiﬁcantly
P  .03) greater than the NK activity detected in the
atients who did not develop autoGVHD despite
reatment with CsA and IFN-.
ytotoxic Effector Molecule Gene Expression in
BMCs
PBMCs from the patients on the autoGVHD in-
uction protocol were serially monitored for perforin,
asL, and granzyme A or B gene expression by real-
ime PCR during the course of treatment (days 12, 19,
5, and 33). Gene expression was determined in the
BMCs of the CsA-treated patients and compared
ith that of the control autologous SCT (non–CsA-
reated) patients, healthy individuals, and allogeneic
CT patients. Figure 1A summarizes the data from
atients evaluated at the onset of autoGVHD (appear-
nce of erythrodermatous rash or biopsy-conﬁrmed
VHD) and from patients who did not have any
linical manifestations of GVHD (data presented are
he 2 highest levels measured during the course of
reatment determined for each patient); perforin and
asL mRNA levels in PBMCs normalized against the
ousekeeping gene GAPDH were evaluated. Com-
ared with healthy individuals, PBMCs obtained from
atients at the onset of autoGVHD had signiﬁcantly
igher mRNA transcript levels for perforin (3.5-fold;
 .01). Perforin mRNA levels in PBMCs from
atients who did not have any clinical manifestations
f autoGVHD were also increased (1.8-fold) com-
ared with the control groups. Expression was signif-
cantly (P 	 .01) less than the levels detected in pa-
ients with autoGVHD. FasL mRNA levels in
BMCs isolated from patients at the onset of au-
imer Sequence (5-3) Probe Sequence (FAM-5-3–TAMRA)
CCGTGTCAGT AGCCCAGAAGACCCACCAGGACCA
TCCATCAGCTGTAAA ACCCAGCCACACGCGAAGGTG
TGACATTTATGG CTGACAGCTGCTCACTGCCAGGGAA
ine.erse Pr
CTCCA
TTTT
CAAGG
rhodamoGVHD, however, were 3.3-fold lower than the lev-
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1ls detected in healthy individuals (P  .03) and 1.5-
old lower than the levels observed in patients who did
ot have any clinical manifestations of autoGVHD.
asL mRNA levels in this latter group of patients were
till signiﬁcantly (P	 .01) less than the levels detected
n PBMCs isolated from healthy individuals. Analysis
igure 1. Expression of cytotoxic effector molecule mRNA in per
BMCs of 8 healthy individuals (black bars), 6 control non–CsA-tre
valuated at the onset of autoGVHD (open bars; n  17 different tim
lease note that identical results (maximal or minimal levels) on 2 su
omplementary DNA was analyzed for effector molecule transcripts
ata were evaluated as effector molecule mRNA levels normali
xpressed as mean 
 SE. Perforin mRNA levels in patients at
anifestations of autoGVHD were signiﬁcantly higher than those
n patients at the onset of autoGVHD were signiﬁcantly lower than
ny clinical manifestations of autoGVHD (P  .03 or P 	 .01, res
RNA levels for patients in whom autoGVHD developed (open bar
RNA transcripts in patients with autoGVHD were signiﬁcantly h
03). FasL mRNA expression at day 26 for patients with autoGVH
yndrome did not develop (P  .04).f granzyme mRNA transcripts in PBMCs is summa- o
60ized in Figure 1B. Granzyme B mRNA levels in
BMCs isolated from patients at the onset of au-
oGVHD and from patients in whom autoGVHD did
ot develop were increased compared with the levels
etected in PBMCs from healthy individuals (3.1-fold
nd 2.2-fold, respectively; P 	 0.01). However, levels
blood mononuclear cells (PBMCs). RNA was harvested from the
tologous stem cell transplantation patients (coarse bars), 15 patients
ts), and 21 patients without autoGVHD (gray bars; n  42 points).
determinations for any given patient were included in the analysis.
ing perforin, FasL (A), and granzyme A or B (B), by real-time PCR.
ainst glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
set of autoGVHD or in patients who did not have any clinical
hy controls (P  .01 or P 	 .01, respectively). FasL mRNA levels
vels detected in healthy individuals or in patients who did not have
ly). Time course sequential analysis of perforin (C) and FasL (D)
patients who did not (gray bars) is demonstrated. Levels of perforin
han the levels detected in patients without GVHD at day 26 (P 
signiﬁcantly lower than for patients in whom this autoaggressionipheral
ated au
e poin
ccessive
, includ
zed ag
the on
in healt
the le
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s) and
igher t
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Bnset of autoGVHD were marginally increased com-
ared with the levels detected in patients in whom this
yndrome did not develop. Granzyme A mRNA levels
ere comparable for all groups. Levels of mRNA
xpression for the cytotoxic molecules in the 6 con-
rol, non–CsA-treated SCT patients were similar, al-
hough FasL mRNA transcripts were increased (but
ot signiﬁcantly) compared with the levels detected in
ealthy individuals. Perforin and granzyme B mRNA
evels in patients at the onset of autoGVHD were
igniﬁcantly higher than the levels in control SCT
non–CsA-treated) patients (3.9-fold and 2.7-fold, re-
pectively; P 	 .01).
Figure 1, C and D, summarizes the temporal anal-
sis of perforin and FasL mRNA expression for pa-
ients in whom autoGVHD developed and for
atients who did not have this experimental autoag-
ression syndrome. Perforin mRNA levels in PBMCs
rom both groups of patients increased after SCT and
eached maximal levels 26 to 33 days after trans-
lantation. Levels of perforin mRNA transcripts in
BMCs from patients with autoGVHD were signiﬁ-
antly (P  .03) higher than the levels detected in
atients without GVHD at day 26. It is of interest to
ote that most (11 of 15) patients experienced the
evelopment of autoGVHD during this interval (be-
ween days 23 and 27) [13,28]. IFN-, IL-18, and
NF- mRNA levels in patients at the onset of au-
oGVHD were signiﬁcantly higher than the levels in
ontrol (non–CsA-treated) SCT patients (3.9-fold,
.7-fold, and 6.4-fold, respectively; P 	 .05). How-
ver, FasL mRNA levels in PBMCs isolated from both
roups of patients on days 12, 19, and 26 were low
ompared with the levels detected in the PBMCs from
ealthy individuals but returned to near-normal levels
y day 33. It is interesting to note that for patients
ith autoGVHD, FasL mRNA levels reached a nadir
t day 26, the height of perforin mRNA expression.
asL mRNA expression at day 26 for patients with
utoGVHD was signiﬁcantly (P  .04) lower even
ompared with patients in whom this autoaggression
yndrome did not develop. The onset and duration of
utoGVHD (average time to onset, day 23; average
uration, 6.4 days) were also concordant with decreas-
ng levels of FasL and increasing levels perforin
RNA transcripts. Comparatively, mRNA levels for
erforin and FasL in 4 patients with grade III to IV
lloGVHD were signiﬁcantly (P 	 .01) increased
ompared with those of healthy individuals (6.1-fold
nd 7.4-fold, respectively).
ytotoxicity-Associated Cytokine Gene Expression
n PBMCs
Although TNF- is critically involved in CTL
ffector function, IFN-, IL-12, and IL-18 are also
mportant for the maturation of CTLs and can mod-
late the effector function (perforin or FasL) of both s
B&MTlymphocytes and NK cells. PBMCs from the pa-
ients on the autoGVHD induction protocol were
erially monitored for cytotoxicity-associated cytokine
ene expression by real-time PCR during the course
f treatment (day 12 through 33). Analysis of IFN-,
NF-, and IL-18 mRNA transcripts in PBMCs is
ummarized in Figure 2A. TNF- mRNA levels in
BMCs isolated from patients at the onset of au-
oGVHD were 8.8-fold higher compared with those
n healthy individuals (P 	 .01). TNF- mRNA levels
data presented report the highest level during the
ssessed time interval) in patients in whom au-
oGVHD did not develop were also increased (5.6-
old) compared with healthy individuals. TNF-
RNA levels in this group of patients were signiﬁ-
antly (P 	 .01) lower compared with the levels de-
ected in patients in whom autoGVHD developed.
evels of IL-18 mRNA were also signiﬁcantly (P 	
01) increased in the PBMCs from both groups of
atients (autoGVHD positive, 2.8-fold; autoGVHD
egative, 1.1-fold) compared with healthy individuals.
learly, the highest levels of IL-18 were detected in
he patients in whom autoGVHD developed. It is
nteresting to note that levels of IFN- mRNA were
electively increased only in the patients who experi-
nced the development of autoGVHD, with a 3.6-fold
ncrease compared with the levels detected in both
ealthy individuals and in patients who did not expe-
ience this autoaggression syndrome (P 	 .01). Be-
ause of very low transcription rates, levels of IL-12
ould not be quantiﬁed in the patient population.
owever, low levels of IL-12 mRNA were detected at
4 of 17 time points for patients with autoGVHD
ompared with only 5 of 42 points for patients who
id not experience the development of autoGVHD
P	 .01; data not presented). Comparatively, levels of
ytokine message in autoGVHD patients were lower
han in patients for whom GVHD developed after
llogeneic SCT (IFN-, TNF-, and IL-18 mRNA
ranscripts were detected at levels of 4.3-fold, 11.4-
old, or 3.2-fold higher compared with healthy indi-
iduals, respectively; P 	 .05). Messenger RNA levels
or IFN-, TNF-, and IL-18 in the PBMCs from
utologous SCT control recipients (not treated with
sA and IFN-) were identical to the levels detected
n healthy individuals.
Figure 2, B and D, summarizes the temporal anal-
sis of IFN-, TNF-, and IL-18 mRNA expression
or patients in whom autoGVHD developed and for
atients in whom this experimental autoaggression
yndrome did not develop. The temporal expression
f IFN- and TNF- mRNA levels in the PBMCs
rom patients with autoGVHD was remarkably simi-
ar to the temporal expression of perforin mRNA.
evels of IFN- and TNF- mRNA detected in
BMCs after transplantation increased in a time-
equential manner and reached maximal levels on day
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16. Levels of these cytokine transcripts were signiﬁ-
antly higher than the levels detected in patients with-
ut GVHD (this was particularly pronounced on day626) or the levels detected in the PBMCs from healthy
ndividuals and in PBMCs from control non–CsA-
reated SCT patients (P 	 .01). A similar pattern was
bserved for the temporal expression of IL-18 post-
ransplantation mRNA levels; there were only modest
ifferences between patients who experienced the de-
elopment of autoGVHD and those who did not.
orrelation between Cytotoxic Activity and
ytotoxic Molecule/Cytokine Expression
The correlations between perforin, FasL, IFN-,
nd TNF- gene expression in PBMCs of autologous
CT recipients who were treated with CsA and IFN-
nd developed signiﬁcant cytolytic killer cell activity is
llustrated in Figure 3A to H. Killing of autologous
HA-blasts mediated by posttransplantation lympho-
ytes correlated with the level of perforin, IFN-, and
NF- mRNA expression in PBMCs (Figure 3A, C,
nd D; P  .01, P 	 .01, and P  .02, respectively).
imilarly, the ability to kill the T47D breast cancer
ell line also correlated with perforin, IFN-, and
NF- gene expression (Figure 3E, G, and H; P 	
01, P  .01, and P  .02, respectively). The NK
ctivity was proportioned to the levels of perforin,
FN-, TNF-, and IL-18 mRNA expression (P 	
.05; data not presented). However, there was a pro-
ressive loss of FasL mRNA expression with increas-
ng cytotoxicity against PHA-blasts and T47D cells
Figure 3, B and F; P  .01 and P  .08, respectively).
ttempts to correlate levels of IL-18 mRNA with the
bility to kill autologous PHA blasts and the T47D
ell line were unsuccessful.
Changes in the cytotoxicity and mRNA expression
igure 2. Expression of cytotoxicity-associated cytokine mRNA in
BMCs. PBMCs from patients on the autoGVHD induction pro-
ocol were serially monitored for IFN-, TNF-, and IL-18 gene
xpression by real-time PCR during the course of treatment (post-
ransplantation days 12, 19, 25, and 33). Gene expression was
etermined in the PBMCs of 36 patients at 4 different time points
nd compared with that of healthy individuals (black bars; n  8),
ontrol non–CsA-treated SCT patients (coarse bars; n  6), pa-
ients evaluated at the onset of autoGVHD (open bars; n  17
ifferent time points for 15 patients), and patients without au-
oGVHD (gray bars; n 42 points for 21 patients). TNF-, IL-18,
nd IFN- mRNA levels in PBMCs from patients at the onset of
utoGVHD were signiﬁcantly higher compared with those of
ealthy individuals (P 	 .01). A, Analysis of IFN-, IL-18, and
NF-. Time course sequential analysis of IFN-, TNF-, and
L-18 mRNA levels for patients in whom autoGVHD developed
open bars) and patients who did not (gray bars) is demonstrated in
through D. Data were evaluated as cytokine mRNA levels nor-
alized against GAPDH and expressed as mean 
 SE. Levels of
FN- and TNF- transcripts were signiﬁcantly higher than the
evels detected in patients without GVHD on day 26 (P 	 .05).
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Bver time were assessed in PBMCs from patients with
utoGVHD after transplantation. Representative ex-
eriments evaluating lymphocytotoxicity and cyto-
oxic molecule expression for 2 patients are shown in
igure 4. NK activity and the ability of the PBMCs
rom patient A to kill T47D tumor cells (autologous
HA blasts were not available for this patient) paral-
eled increased perforin gene expression and decreased
asL gene expression (Figure 4A). Similarly, the abil-
ty of PBMCs from patient B to kill autologous PHA-
lasts and the NK cell line K562 exhibited an identical
emporal relationship with increased TNF- gene ex-
ression and decreased FasL gene expression (Figure
B). Both patients experienced the development of
linical cutaneous GVHD concordant with the devel-
pment of the killer cell activity.
ytotoxic Effector Molecule and Cytokine Gene
xpression in Skin Lesions of GVHD
To conﬁrm the pathogenic involvement of cyto-
ines and cytotoxic effector molecules in GVHD,
ene expression was evaluated in the skin lesions of 2
atients with autoGVHD. Comparisons were also
ade of skin biopsy samples from 4 patients with
lloGVHD by real-time PCR. Figure 5 summarizes
he data evaluating mRNA levels normalized against
APDH. Comparable levels of perforin and gran-
igure 3. Correlation between cytotoxic killer cell function and cy
xpression and the ability to kill either autologous PHA blast cells o
f autoGVHD. Cytotoxicity against autologous PHA-blasts (A-D)
1Cr release assay at a 100:1 effector-target ratio. The relative exp
gainst GAPDH was determined by real-time PCR.yme B cytotoxic effector molecules and IFN-, t
B&MTNF-, and IL-18 cytokine mRNA transcripts were
etected in the skin lesions of patients with au-
oGVHD and alloGVHD. Although pronounced lev-
ls of FasL mRNA transcripts were detected in skin
esions of all patients with alloGVHD, FasL mRNA
ranscripts either were not detected or were margin-
lly expressed in the skin lesions of patients with
utoGVHD.
ellular Origin of Cytotoxic Effector Molecules
nd Cytokine Transcription
To identify the cellular source of the IFN-,
NF-, IL-18, perforin, and FasL mRNA transcripts,
D4 and CD8 T cells and monocytes were sepa-
ated from PBMCs of 5 healthy individuals and 7
atients who received CsA after autologous SCT.
wo patients had clinical autoGVHD with detectable
ytotoxicity against autologous PHA-blasts (14.2% or
5.5%, respectively; effector-target ratio, 100:1).
ene expression was determined in each population.
he results in Figure 6 show that perforin mRNA
evels in both the CD4 and CD8 subset in whom
utoGVHD developed were markedly higher com-
ared with the levels from both healthy individuals
nd patients in whom autoGVHD did not develop
P 	 .05). However, FasL mRNA levels were rela-
ively lower in the CD4 and CD8 subsets of pa-
molecule/cytokine mRNA expression. Correlation between gene
47D breast cancer cell line was examined in 11 patients at the onset
breast cancer cell line T47D (E-H) was measured with a standard
of perforin, FasL, IFN-, and TNF- mRNA levels normalizedtotoxic
r the T
or the
ressionients in whom autoGVHD developed compared with
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1igure 4. Relationship between the induction of autoGVHD and cytotoxic activity/molecule expression. The changes in the cytotoxic activity
nd effector molecule expression over time were assessed in PBMCs from 2 representative patients (patient A, panel A; patient B, panel B) with
utoGVHD (the interval of biopsy-conﬁrmed erythematous rash is highlighted in the ﬁgure) after transplantation. Cytotoxicity against
utologous PHA-blasts, K562 NK target cell lines, and the T47D breast cancer cell line were measured with a standard 51Cr release assay at
100:1 effector-target ratio. The relative expression of perforin, FasL, and TNF- mRNA levels normalized against GAPDH was determined
y real-time PCR.igure 5. Expression of cytotoxicity-associated molecule and cytokine mRNA in skin lesions. RNA was harvested from skin lesions of 2 patients
ith autoGVHD or 4 patients with alloGVHD. Complementary DNA was analyzed for effector molecule and cytokine transcription,
ncluding perforin, FasL, granzyme B, IFN-, TNF-, and IL-18, by real-time PCR. Data were normalized against GAPDH.
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Both healthy individuals (P 	 .05) and patients in
hom this autoaggression syndrome did not develop.
FN- mRNA levels in the CD8 subset from pa-
igure 6. Expression of cytotoxicity-associated molecule and cytokin
eparated from the PBMCs of 5 healthy individuals and 7 patients w
patients. Lymphocytes were separated into distinct T-cell subset
97%. Relative transcripts were determined as follows: 1/(CTtargetients in whom autoGVHD developed were higher h
B&MTompared with the levels from healthy individuals
P 	 .05). TNF- mRNA levels in the CD4 subset
rom patients in whom autoGVHD developed were
A in PBMC subsets. CD4 cells, CD8 cells, and monocytes were
eived CsA after transplantation. Clinical autoGVHD developed in
immunomagnetic beads. The purity of CD4 or CD8 cells was
GAPDH) 2  104.e mRN
ho rec
s with
 CTigher compared with the levels from healthy individ-
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1als (P 	 .01), whereas the levels in the CD8 subset
ere lower. IL-18 mRNA levels in both the CD4
nd CD8 subset in whom autoGVHD developed
ere higher compared with the levels from healthy
ndividuals (P 	 .01). Attempts to correlate these lev-
ls of mRNA in the monocytes subset were unsuccess-
ul. Comparatively, these mRNA levels in both CD4
nd CD8 cells from 4 patients with grade III to IV
lloGVHD were signiﬁcantly increased (P 	 .01) ex-
ept for IL-18 in CD8 cells.
ISCUSSION
This study examined the autocytotoxic T cells
ssociated with autoGVHD and their molecular path-
ays as assessed by the expression of cytokine- and
ytotoxicity-associated genes. The results provide sev-
ral new insights into the effector and regulatory
echanisms associated with this novel autoimmune
yndrome. Levels of mRNA transcripts for the cyto-
ytic molecules perforin and granzyme B and the cy-
otoxicity-associated cytokines IFN-, TNF-, and
L-18 were markedly increased in the PBMCs from
atients with autoGVHD compared with the levels
etected in PBMCs from healthy individuals and from
ontrol, non–CsA-treated SCT patients. To a large
xtent, the results parallel the ﬁndings in alloGVHD,
n which cytotoxicity-associated molecules and cyto-
ines play an important role in the pathogenesis of
VHD [21-27]. Moreover, temporal posttransplanta-
ion analysis also revealed that peak expression of both
ytolytic molecule– and cytotoxicity-associated cyto-
ine mRNA transcripts was associated with the onset
f clinical evidence of autoGVHD in most patients
13,28].
It is interesting to note that with the exception of
FN-, enhanced expression of the cytotoxicity-asso-
iated molecule and cytokine mRNA transcripts was
ot limited to patients in whom autoGVHD devel-
ped. PBMCs from SCT patients treated with CsA
ut who did not have autoGVHD also had increased
evels of mRNA transcripts for perforin, granzyme B,
NF-, and IL-18. Expression, however, was sub-
tantially lower compared with that in patients in
hom autoGVHD developed. Because the levels of
he cytolytic molecule– and cytotoxicity-associated cy-
okine mRNA in control non–CsA-treated SCT pa-
ients were comparable to those of healthy individuals,
t seems likely that the expression of these mRNA
ranscripts in patients who did not have autoGVHD
ere due to the CsA plus IFN- treatment regimen.
he reduced levels of these cytokines in patients who
id not experience autoGVHD development may be
ue to the limited ampliﬁcation of the effector mech-
nisms and may reﬂect a subclinical autoGVHD.
owever, there was a selective increase in mRNA l
66evels for IFN- only in patients in whom autoGVHD
eveloped. These results suggest that IFN- plays an
ssential role in the development of clinical disease.
ecause IFN- is administered exogenously in the
reatment regimen, it seems likely that local produc-
ion of this cytokine by the effector T cells in the
atients who have clinical autoGVHD is critical. Lo-
al production of IFN- would lead to the upregula-
ion of the MHC class II target antigen in the target
issue, allowing target cell recognition and destruc-
ion. In accord are the results from a rat model of
utoGVHD, which showed that local upregulation of
he MHC class II target antigen by IFN- is impor-
ant for the onset of autoimmune pathology [37].
It is important to note that expression of the cy-
otoxicity-associated molecule and cytokine mRNA
ranscripts occurred during CsA treatment; this sug-
ests that activation of the cells and the signaling
athways leading to the production of these tran-
cripts may be relatively resistant to the effects of this
mmunosuppressive drug. The relative resistance of
hese pathways may have signiﬁcant consequences.
ailure to adequately suppress production of the cy-
olytic molecule and cytotoxicity-associated cytokine
RNA transcripts may compromise the efﬁcacy of
sA-based immunosuppression in certain settings, in-
luding allogeneic SCT and the prevention of
VHD, that use these cytokines and cytolytic effector
olecules [21-27].
The induction of autoGVHD correlates with the
ppearance of MHC class II–dependent cytotoxic ac-
ivity against autologous PHA-blasts mediated by au-
oreactive CD8 T cells. Consistent with this obser-
ation are the results demonstrating that expression of
erforin and IFN- mRNA transcripts was increased
n CD8 cells and that autocytolytic killer cell func-
ion correlated with the increased expression of these
RNA transcripts. Enhanced expression of perforin
nd TNF-mRNA in CD4T cells was also detected
n patients in whom autoGVHD developed. It is in-
eresting to note that NK activity recovered quickly
fter SCT and was maintained in the CsA-treated
CT patients: this ﬁnding is consistent with increased
erforin, TNF-, IFN-, and IL-18 gene expression.
ecent studies, however, demonstrate that the CD8
-cell subset is the major effector mechanism in au-
oGVHD, although NK cells may contribute to the
istologic damage observed [15,16]. However, there
as a progressive loss of FasL mRNA expression in
he context of increasing cytotoxicity against PHA-
lasts and T47D cells. Messenger RNA levels for both
erforin and FasL in the PBMCs from 4 patients with
rade III to IV alloGVHD were markedly increased.
t is interesting to note that perforin mRNA tran-
cripts were detected in the skin lesions of both pa-
ients with autoGVHD and alloGVHD, whereas high
evels of FasL transcripts were detected only in the
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Effector Mechanisms in Autologous GVHD
Batients with alloGVHD. FasL mRNA transcripts in
he patients with autoGVHD either were not detected
r were marginally expressed—certainly a remarkable
ifference between alloGVHD and autoGVHD.
aken together, these ﬁndings imply that perforin/
ranzyme, rather than FasL, is crucial for the patho-
ogic damage mediated by the autoreactive T cells in
utoGVHD. This is in contrast to the relative impor-
ance of FasL in alloGVHD [21-27].
Therapeutic immune modulation has been ex-
lored in several clinical trials of autoGVHD in an
ttempt to enhance antitumor immunity after autolo-
ous SCT. Moreover, the ability to experimentally
nduce autoaggression may reveal unique insights into
utoreactive and autoregulatory mechanisms. The in-
uction of autoGVHD requires both the active inhi-
ition of the thymic-dependent clonal deletion of au-
oreactive T cells and the elimination of peripheral
mmunoregulation [38-41]. Both CD4 and CD8
utoreactive T cells are clearly important and play
istinct roles in the onset and progression of disease,
s demonstrated in an adoptive transfer model of au-
oGVHD in the rat [4,5]. CD8 autoreactive T cells
an transfer the acute phase of autoGVHD that re-
olves within 2 weeks, whereas CD4 cells are inef-
ective by themselves. Adoptive transfer of both sub-
ets, however, results in autoaggressive disease with
reater intensity that can progress into a sustained
hronic phase. The autoreactive CD4 T-cell subset
ertainly seems to play a critical role in autoGVHD.
n accord are the results from this study, which show
hat IFN-/perforin–based CD8 CTLs seem to play
dominant role in autoGVHD and that TNF-/
erforin–based CD4 cells may amplify this autoag-
ressive syndrome.
Of additional importance are the ﬁndings that
NF- mRNA transcripts were also upregulated in
BMCs, including CD4 T cells, from patients in
hom autoGVHD developed. TNF- secreted by
ctivated lymphocytes can act directly as an effector
athway in target cell killing [19,42]. The results from
his study also demonstrate that cytotoxicity against
utologous PHA-blasts mediated by autoreactive T
ells correlated with increased expression of TNF-
RNA. The increase in TNF- mRNA expression
lso correlated with the clonal expansion of autoreac-
ive T cells in patients in whom autoGVHD devel-
ped [7]. Because TNF- is also required for optimal
aturation of CTLs [43], it seems likely that this
ytokine plays a role in the development of autoreac-
ive CTLs in autoGVHD. Moreover, upregulation of
oth perforin and TNF- mRNA in CD4 T cells
rom patients with autoGVHD suggests that this sub-
et can contribute to the pathology of autoGVHD and
an amplify or mature CD8 autoreactive effector T
ells. In addition, TNF- also induces IFN- produc-
ion [44,45]. As described previously, IFN- plays a a
B&MTritical role in the development of autoGVHD [37].
learly, TNF-, with its proinﬂammatory actions,
an mediate direct damage and amplify the autoreac-
ive T-cell response in this disease.
The most pronounced and unexpected ﬁnding
rom this study was the decrease in FasL mRNA
ranscripts detected in both the CD4 and CD8 cells
f patients in whom autoGVHD developed. Levels of
asL mRNA transcripts were decreased even in the
resence of increased levels of IL-18, a cytokine that
romotes FasL expression [46,47]. One potential ex-
lanation is that there is a cytotoxic dysregulation that
nsues with the onset of autoaggression. Alternatively,
he autoreactive T cells associated with this syndrome
ay have aberrant signaling pathways. Certainly, CsA
reatment alters T-cell differentiation and may disrupt
he expression of classic cell-surface/intracellular sig-
aling mechanisms [40,41]. However, the progressive
oss of FasL mRNA expression as MHC class II–
ependent autologous lymphocytotoxicity increased
uggests that the FasL pathway may be relevant for
he regulation of this immune syndrome. Previous
tudies indicate that the release of autoreactive T cells
nto the periphery by itself is not sufﬁcient to induce
utoGVHD; a peripheral autoregulatory system must
e eliminated to provide a permissive environment for
he autoreactive T cells to manifest autoaggression
nd allow for the development of autoGVHD [48,49].
ecent studies in the rat model suggest that the auto-
egulatory T cells mediate a peripheral clonal deletion
f autoreactive T cells that is Fas/FasL dependent
50]. The results from this study showed a reduction
n FasL in both CD4 and CD8 T cells in patients
ith autoGVHD; a progressive increase in autologous
ymphocytotoxicity suggested the possibility that
ownregulation of FasL expressed by autoregulatory
ells leads to the development of autoGVHD. Alter-
atively, there may be a failure to reconstitute the
utoregulatory compartment. In this regard, recent
tudies indicate that CsA treatment impedes the de-
elopment of autoregulatory T cells in the thymus
51].
IL-18, a multifunctional cytokine, was originally
iscovered as a factor that induced IFN- production
rom lymphocytes and monocytes [52,53]. IL-18 up-
egulates FasL expression on T cells and NK cells
46,47], facilitating killing activity and participating in
he development of alloGVHD. In contrast, Reddy et
l. [54] provided substantial evidence that IL-18 reg-
lates alloGVHD by inducing Fas-mediated apoptosis
f donor T cells, presumably mediated by reduced
NF- production. However, in human autoGVHD,
oth IL-18 and TNF- mRNA transcripts are in-
reased, whereas FasL mRNA transcripts are paradox-
cally decreased in patients in whom autoGVHD de-
elops. These results suggest that the development of
utoGVHD and its respective pathology is not depen-
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1ent on IL-18 and Fas/FasL-mediated cytolysis.
owever, recent studies demonstrate that IL-18 aug-
ents perforin-mediated and IFN-–mediated NK
ytic activity [55,56]; these ﬁndings are in accord with
hose of the present study, which show that the induc-
ion of autoGVHD correlates with perforin-, IFN-–,
nd IL-18–dependent NK activity. In addition, IL-12
a cytokine that can augment perforin-dependent lytic
ctivity collaboratively with IL-18) mRNA could be
etected in most patients in whom autoGVHD devel-
ped [57].
Collectively, the results from this study indicate
hat the autoreactive T cells make differential use of
ytotoxic pathways for the induction and regulation of
utoGVHD, as schematically illustrated in Figure 7.
n human autoGVHD, the perforin/granzyme B and
NF- pathways are critically important for the au-
oreactive T-cell response and promote destruction of
elf. Essential to this process is IFN-, which may not
nly enhance CTL function but also induce local
pregulation of the MHC class II target antigen. The
asL pathway, however, seems to play a central role in
he regulation of this immune syndrome. In particular,
t is controversial which pathway has greater relative
ontribution to alloGVHD or a graft-versus-tumor
ffect [25,26]. Recent experiments indicate that the
erforin pathway, rather than the Fas/FasL pathway,
s more important for the graft-versus-tumor effect
eparated from alloGVHD [54]; this is an expected
dvantageous beneﬁt of such a cytotoxic pathway in
utoGVHD. Understanding these pathways and the
anipulation of autoreactive and autoregulatory ac-
ivity through the effector pathways may facilitate the
evelopment of more effective immunotherapeutic
trategies for enhancing the antitumor efﬁcacy of au-
oGVHD, including the speciﬁc blockade of FasL to
Figure 7. Schematic model of effectonhibit autoregulatory mechanisms.
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